GLP-1 drugs and kidney stones: read the trial signal precisely

A current Wegovy label reports a kidney-stone-related signal in one cardiovascular outcomes trial: urolithiasis occurred in 1.2% of participants assigned Wegovy injection and 0.8% assigned placebo; serious urolithiasis occurred in 0.6% and 0.4%, respectively. Those figures justify a conversation about a person’s stone history. They do not prove that semaglutide caused every event, predict an individual’s risk, or establish a class-wide risk for every GLP-1 medicine.¹

The answer is easy to distort because three different kidney topics share search language. Urolithiasis refers to stones in the urinary tract. Acute kidney injury is a change in kidney function, and chronic kidney disease is a longer-term condition or treatment indication. A gallstone is in a different organ system altogether. Evidence for one cannot be substituted for another.

Place the label numbers in their actual trial

The label’s percentages come from one trial of Wegovy injection involving adults with established cardiovascular disease and overweight or obesity; people with diabetes were excluded. The study did not randomize participants to every GLP-1 receptor agonist, a Wegovy tablet, or the later 7.2 mg high-dose regimen. Its safety collection and follow-up were structured for that cardiovascular trial, not as a dedicated stone-recurrence study.¹

The absolute difference in the reported overall proportions is 0.4 percentage points within this study. That arithmetic is useful for reading the record, but it should not be translated into a “number needed to harm” for an individual. The label does not make this a controlled study of stone mechanisms, prior stone history, or prevention strategies. Rounding and the way events were collected also limit overly precise comparisons.

The Wegovy HD approval guide covers a distinct dose and use question. Its 7.2 mg discussion must not inherit a stone-event rate from the cardiovascular trial’s lower-dose injection schedule without qualification.

What a stone-former urine study measured

A small retrospective study examined 44 people with a history of kidney stones who were receiving a GLP-1-based therapy. Researchers compared 24-hour urine measurements before and after treatment. Some measured urine constituents changed, while the stone-formation supersaturation indices did not change significantly.²

That is a urine-chemistry study, not a trial of how often new stones occurred. It cannot establish that the medicine prevents stones, causes stones, or is neutral for an individual with prior episodes. Its participants had an existing stone history and were not randomized to a treatment, so the results also should not override the larger Wegovy label signal. Conversely, the label signal alone cannot tell us what happened to those 44 stone formers over years.

When a clinic cites “a kidney-stone study,” ask which endpoint it measured: a urine value, a suspected stone, a confirmed clinical stone event, or a serious event. The distinction is the information gain; the mere word “kidney” does not make the studies comparable.

Why comparator studies have not closed the question

A 2026 systematic review gathered six observational studies comparing GLP-1 receptor agonists with other active antidiabetic drugs for stone outcomes. The review assessed the evidence as vulnerable to moderate bias and called for prospective studies with stone-specific endpoints.³

An active-comparator result can reflect differences in the comparator drug, the populations selected for each treatment, other medicines, health conditions, and how stones were identified. A lower observed event rate in one group is not proof that the other medicine caused stones. Nor does a review of mixed GLP-1 products supply a product-specific risk estimate for a person considering Wegovy.

This is why a useful consultation should not collapse trial percentages, urine chemistry and observational comparisons into “GLP-1s cause stones” or “GLP-1s protect kidneys.” The semaglutide kidney injury versus CKD guide addresses kidney-function warnings and indications, while the gallbladder guide addresses a separate organ and set of events.

Questions to bring to a weight-care visit

If stones are part of your history, bring the dates and any records identifying stone type, recurrence, prior evaluation, and current kidney-related conditions. Bring the exact drug and formulation being considered. A clinician can then assess whether the published population resembles your situation and what additional information is needed.

Ask:

• Which exact product and dose does the cited safety figure cover?
• Was the outcome a urinary stone, acute kidney injury, or gallstone?
• Does the evidence include people with a stone history like mine?
• Who will evaluate a new urinary symptom or a suspected stone, and how will that clinician communicate with the weight-care prescriber?
• What finding would change the proposed treatment plan?

A medical weight-loss practice listing cannot answer those questions on its own. The practical answer is a product-specific, history-aware discussion that respects the trial’s small absolute difference and the remaining uncertainty, without making a class-wide claim from one label table.